Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of EGF816 in EGFR-mutant advanced non-small cell lung cancer
NL-OMON52991Phase 2Active, not recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Feb 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nazartinib in non-small cell lung cancer (NSCLC), sponsored by Netherlands Cancer Institute. Primary endpoints: Maximum tolerated dose, Recommended phase II dose and 1 more. Started Feb 2017; status: active, not recruiting.
02
Drugs
nazartinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON52991.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52991.